全文获取类型
收费全文 | 777篇 |
免费 | 34篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 26篇 |
妇产科学 | 8篇 |
基础医学 | 135篇 |
口腔科学 | 7篇 |
临床医学 | 65篇 |
内科学 | 200篇 |
皮肤病学 | 11篇 |
神经病学 | 79篇 |
特种医学 | 21篇 |
外科学 | 60篇 |
综合类 | 3篇 |
预防医学 | 22篇 |
眼科学 | 7篇 |
药学 | 107篇 |
肿瘤学 | 62篇 |
出版年
2021年 | 6篇 |
2020年 | 6篇 |
2019年 | 9篇 |
2018年 | 7篇 |
2017年 | 8篇 |
2016年 | 10篇 |
2015年 | 9篇 |
2014年 | 21篇 |
2013年 | 10篇 |
2012年 | 39篇 |
2011年 | 38篇 |
2010年 | 26篇 |
2009年 | 31篇 |
2008年 | 42篇 |
2007年 | 36篇 |
2006年 | 50篇 |
2005年 | 60篇 |
2004年 | 45篇 |
2003年 | 53篇 |
2002年 | 43篇 |
2001年 | 10篇 |
2000年 | 9篇 |
1999年 | 13篇 |
1998年 | 7篇 |
1997年 | 8篇 |
1996年 | 13篇 |
1995年 | 7篇 |
1994年 | 9篇 |
1993年 | 6篇 |
1992年 | 4篇 |
1990年 | 8篇 |
1989年 | 5篇 |
1988年 | 7篇 |
1987年 | 4篇 |
1986年 | 6篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1982年 | 7篇 |
1981年 | 14篇 |
1980年 | 10篇 |
1979年 | 5篇 |
1978年 | 6篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1965年 | 4篇 |
1957年 | 4篇 |
1941年 | 6篇 |
1936年 | 3篇 |
1935年 | 3篇 |
1927年 | 3篇 |
排序方式: 共有813条查询结果,搜索用时 15 毫秒
11.
Anna Lam MD Thomas Küffer MSc Lukas Hunziker MD Nikolas Nozica MD Babken Asatryan MD PhD Florian Franzeck MD Antonio Madaffari MD Andreas Haeberlin MD PhD Aline Mühl MSc Helge Servatius MD Jens Seiler MD Fabian Noti MD Samuel H. Baldinger MD Hildegard Tanner MD Stephan Windecker MD Tobias Reichlin MD Laurent Roten MD 《Journal of cardiovascular electrophysiology》2021,32(6):1610-1619
12.
13.
Felix Keil Peter Kalhs Oskar A. Haas Gerhard Fritsch Elisabeth Reiter Christine Mannhalter Klaus Lechner Gerda Leitner & Hildegard T. Greinix 《British journal of haematology》1997,97(1):161-164
We present a patient who underwent sibling allogeneic BMT because of refractory Ph+ve ALL and remained BCR-ABL-positive after marrow grafting. Haemopoietic precursor cells were predominantly BCR-ABL-negative and of donor origin. In T cells an exclusively donor genotype was demonstrated. Despite donor leucocyte infusion (DLI), 20 weeks after BMT BCR-ABL fusion mRNA increased in semiquantitative polymerase chain reaction and leukaemic infiltration of the patient's bone marrow was seen. After a second course of DLI the patient achieved sustained molecular remission but he developed severe graft-versus-host disease (GvHD) and died from bacterial sepsis 9 months after DLI. 相似文献
14.
Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization 总被引:12,自引:0,他引:12
Kandzari DE Berger PB Kastrati A Steinhubl SR Mehilli J Dotzer F Ten Berg JM Neumann FJ Bollwein H Dirschinger J Schömig A;ISAR-REACT Study Investigators 《Journal of the American College of Cardiology》2004,44(11):2133-2136
OBJECTIVES: We examined clinical outcomes in the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment (ISAR-REACT) trial based on the duration of pretreatment with a 600-mg loading dose of clopidogrel. BACKGROUND: The influence of the treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization on early outcomes remains uncertain. METHODS: Among 2,159 patients with coronary disease who underwent percutaneous coronary intervention (PCI) in the ISAR-REACT trial, we examined clinical outcomes relative to the duration of pretreatment with a 600-mg dose of clopidogrel: (2 to 3 h, 3 to 6 h, 6 to 12 h, or >12 h). Patients were randomly assigned to adjunctive therapy with abciximab or placebo at the beginning of the study. The primary end point was a composite of death, myocardial infarction, or urgent revascularization within 30 days after randomization. RESULTS: No significant differences were observed between patient groups regarding the duration of pretreatment, irrespective of assignment to abciximab or placebo (p = 0.27 for interaction among abciximab/clopidogrel and placebo/clopidogrel treatment at each time interval). Occurrence of major bleeding also did not differ according to time of initial clopidogrel dosing. CONCLUSIONS: For low-to-intermediate risk patients treated with a 600-mg loading dose of clopidogrel before PCI, incremental clinical benefit within the first 30 days from durations of pretreatment >2 to 3 h was not evident. 相似文献
15.
Daniela Münch Ina Engels Anna Müller Katrin Reder-Christ Hildegard Falkenstein-Paul Gabriele Bierbaum Fabian Grein Gerd Bendas Hans-Georg Sahl Tanja Schneider 《Antimicrobial agents and chemotherapy》2015,59(2):772-781
Oritavancin is a semisynthetic derivative of the glycopeptide antibiotic chloroeremomycin with activity against Gram-positive pathogens, including vancomycin-resistant staphylococci and enterococci. Compared to vancomycin, oritavancin is characterized by the presence of two additional residues, a hydrophobic 4′-chlorobiphenyl methyl moiety and a 4-epi-vancosamine substituent, which is also present in chloroeremomycin. Here, we show that oritavancin and its des-N-methylleucyl variant (des-oritavancin) effectively inhibit lipid I- and lipid II-consuming peptidoglycan biosynthesis reactions in vitro. In contrast to that for vancomycin, the binding affinity of oritavancin to the cell wall precursor lipid II appears to involve, in addition to the d-Ala-d-Ala terminus, other species-specific binding sites of the lipid II molecule, i.e., the crossbridge and d-isoglutamine in position 2 of the lipid II stem peptide, both characteristic for a number of Gram-positive pathogens, including staphylococci and enterococci. Using purified lipid II and modified lipid II variants, we studied the impact of these modifications on the binding of oritavancin and compared it to those of vancomycin, chloroeremomycin, and des-oritavancin. Analysis of the binding parameters revealed that additional intramolecular interactions of oritavancin with the peptidoglycan precursor appear to compensate for the loss of a crucial hydrogen bond in vancomycin-resistant strains, resulting in enhanced binding affinity. Augmenting previous findings, we show that amidation of the lipid II stem peptide predominantly accounts for the increased binding of oritavancin to the modified intermediates ending in d-Ala-d-Lac. Corroborating our conclusions, we further provide biochemical evidence for the phenomenon of the antagonistic effects of mecA and vanA resistance determinants in Staphylococcus aureus, thus partially explaining the low frequency of methicillin-resistant S. aureus (MRSA) acquiring high-level vancomycin resistance. 相似文献
16.
17.
Hösel M Broxtermann M Janicki H Esser K Arzberger S Hartmann P Gillen S Kleeff J Stabenow D Odenthal M Knolle P Hallek M Protzer U Büning H 《Hepatology (Baltimore, Md.)》2012,55(1):287-297
Adeno-associated viral vectors (rAAV) are frequently used in gene therapy trials. Although rAAV vectors are of low immunogenicity, humoral as well as T cell responses may be induced. While the former limits vector reapplication, the expansion of cytotoxic T cells correlates with liver inflammation and loss of transduced hepatocytes. Because adaptive immune responses are a consequence of recognition by the innate immune system, we aimed to characterize cell autonomous immune responses elicited by rAAV in primary human hepatocytes and nonparenchymal liver cells. Surprisingly, Kupffer cells, but also liver sinusoidal endothelial cells, mounted responses to rAAV, whereas neither rAAV2 nor rAAV8 were recognized by hepatocytes. Viral capsids were sensed at the cell surface as pathogen-associated molecular patterns by Toll-like receptor 2. In contrast to the Toll-like receptor 9-mediated recognition observed in plasmacytoid dendritic cells, immune recognition of rAAV in primary human liver cells did not induce a type I interferon response, but up-regulated inflammatory cytokines through activation of nuclear factor κB. CONCLUSION: Using primary human liver cells, we identified a novel mechanism of rAAV recognition in the liver, demonstrating that alternative means of sensing rAAV particles have evolved. Minimizing this recognition will be key to improving rAAV-mediated gene transfer and reducing side effects in clinical trials due to immune responses against rAAV. 相似文献
18.
Hildegard Koller Peter Keil Franz Seibert 《Archives of orthopaedic and trauma surgery》2013,133(3):343-349
Background
Pelvic ring injuries with associated hemorrhage from the presacral venous plexus are major contributors to morbidity and mortality in trauma patients. The Pelvic C-Clamp is an often discussed, yet seldom used device for both skeletal and hemodynamic stabilization. In a recent study we have addressed this issue and have stressed the importance of regular training sessions with the device. This study is aimed as an extended follow up with a special focus on how trained skills are retained over time.Materials and methods
32 participants with various levels of training were taught to use the clamp. Thirty-six hours later, a hands-on session was performed where the time needed for placement and accuracy of placement were evaluated on a model in individual and team settings. 12 months later a re-evaluation was performed.Results
Evaluation showed that during the first session, 57/64 pins (89.15 %) were placed inside the safe area. The team training results showed reduced times for assembly and more exact pin placement. In the re-evaluation 1 year later, 75 % of all pins were safely placed and the time needed for assembly was significantly longer.Conclusions
The majority of 57 pins were placed in the safe area within 6 min after one single training session. This reproduces the Australian data and supports the theory that adequately educated and skilled physicians should be able to handle the device properly. The data from the re-evaluation suggest that repeating the training session with the device improves performance. 相似文献19.
20.
Stefan Hatzl Florian Posch Alexander Deutsch Christine Beham-Schmid Herbert Stöger Hildegard Greinix Martin Pichler Peter Neumeister Katharina T. Prochazka 《Hematological oncology》2020,38(3):277-283
Overexpression of bcl-2 and c-myc are defining features of double-expressor-lymphoma (DEL) but may also occur separately in patients with primary central nervous system lymphoma (PCNSL). Despite all progress in optimizing treatment regimen, there is lack of sufficient risk stratification models. Here, we first describe the relationship between DEL biology, the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI), treatment response, disease progression, and mortality in PCNSL. In this study, we determined c-myc and bcl-2 status immunohistochemically in samples of 48 patients with newly diagnosed PCNSL and followed these patients for a median interval of 6.2 years. Twelve, 18, and 17 patients harbored none, one, or both DEL features. Corresponding overall response rates after first-line therapy were strongly associated with DEL biology (100%, 42%, and 44% in patients with 0, 1, or 2 DEL features). Patients with one or both DEL features had a 5-fold and 13-fold higher 5-year risk of progression and/or death than patients without DEL features. These associations prevailed after adjusting for the NCCN-IPI. DEL improved the discriminatory capability of the NCCN-IPI (P = .0001). Furthermore, we could show that addition of DEL biology to the NCCN-IPI significantly improved the score's discriminatory potential both toward progression-free survival (increase in Harell's c = 0.15, P = .005) and overall survival (increase in Harell's c = 0.11, P = .029). In conclusion, DEL biology is a strong and simple-to-use predictor of adverse outcome in PCNSL. Addition of DEL to the NCCN-IPI improves its prognostic potential. Disease progression from PCNSL harboring both DEL features is invariably fatal. This defines a novel PCNSL patient subset with a great unmet need for improved therapy. 相似文献